Research Highlights
Honors & Awards
What We Are Doing About:
Benefiting Humanity
Overview
History
Visiting the Institute
From Basic Research to Benefiting Humanity
In the 1980s, Prof. Eli Canaani isolated two genes that abnormally swap pieces of genetic material and lead to the production of a fused protein that triggers chronic myelogenous leukemia (CML). It was the first discovery of cancer produced by protein fusion.
Application
Canaani’s research provided the foundation for the development of Glivec (known as Gleevec in the US), the first drug based on the molecular understanding of a specific cancer. Produced by Novartis, it was approved in 2001 by the FDA and is now routinely prescribed around the world to patients with CML.
